Level D· Scientific groundwork from lab and animal studiesNarrative ReviewEurope PMCOpen access

Research Progress on Biomaterials with Immunomodulatory Effects in Bone Regeneration

Li J., Qu Y., Chu B., Wu T., Pan M., Mo D.

Narrative Review on Immune Modulation, published in Adv Sci (Weinh) (2025) — summary generated from the PubMed abstract.

Open my reading list
Level D· Scientific groundwork from lab and animal studiesEvidence level of this study

Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.

  • Level A · Stronger Clinical Evidence
  • Level B · Emerging clinical evidence with positive signals
  • Level C · Early human research exploring benefits
  • Level D · Scientific groundwork from lab and animal studies
  • Emerging · Emerging topic under active research
Read the A–D evidence level guide

This page is generated from the PubMed record. The Thai description is an automated summary of bibliographic fields and the abstract, not a full translation, and is not medical advice.

Study type
Narrative Review
Journal
Adv Sci (Weinh) (2025)
Reported sample size
—
Source database
Europe PMC
PMID
40799152
PMCID
PMC12412535
DOI
10.1002/advs.202501209
Citations
12

Abstract (original English)

The immune system plays a pivotal role in bone regeneration, and biomaterials engineered to modulate immune responses present a promising strategy for the treatment of extensive bone defects and osteolytic conditions. This review critically evaluates recent advancements in immunomodulatory biomaterials for bone repair, integrating perspectives from both immunology and materials science. It offers a comprehensive analysis of key design strategies and the underlying principles guiding the development of these biomaterials, with a particular focus on their physical and chemical properties, bioactive molecule delivery systems, cell transplantation techniques, and responses to external stimuli. Additionally, this review examines the interactions between these biomaterials and immune cells, particularly macrophages, within various pathological contexts. Finally, the paper discusses current challenges and future directions, aiming to provide researchers and clinicians with a valuable resource for advancing this rapidly evolving field.

What this study does not prove

  • • This study does not prove SVF is an approved treatment or a replacement for standard care.
  • • This is a narrative review: it collects no new patient data and does not systematically appraise evidence quality.

Evidence level

Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.

How we grade evidence
OsteoclastsAnimalsHumansImmunologic FactorsBiocompatible MaterialsBone RegenerationPorosityImmunomodulationImmunomodulating Agents

Browse all related research

Filter the research library by this study's title keywords, author, or publication year.

Related research